Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Umut Demirci

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
The New England Journal of Medicine|June 2, 2025
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based ChemotherapyGiannis Mountzios, Longhua Sun, Byoung Chul Cho, et al.
Annals of Surgical Oncology|February 3, 2021
The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry StudyAtilla Soran, Lutfi Dogan, Arda Isik, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 10, 2026
Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group StudyNazım C Demircan, Melek Özdemir, Sevinç Ballı, et al.
Current Oncology (Toronto, Ont.)|October 28, 2025
Locoregional Treatment in De Novo Bone-Only Metastatic Breast Cancer: Prospective, Multi-Institutional Real-World Data, BOMETIN, Protocol MF14-1aAtilla Soran, Berk Göktepe, Berkay Demirors, et al.
Medicine|November 14, 2023
The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from TurkeyArif Akyildiz, Deniz Can Guven, Ahmet Anil Ozluk, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|September 12, 2015
Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinomaNedim Turan, Mustafa Benekli, Olcun Umit Unal, et al.
Medicine|May 24, 2024
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacySaadettin Kilickap, Akin Ozturk, Nuri Karadurmus, et al.
Lung Cancer (Amsterdam, Netherlands)|August 18, 2020
GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patientsNir Peled, Roni Gillis, Saadettin Kilickap, et al.
Therapeutic Advances in Medical Oncology|March 16, 2026
Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter studyTaha Koray Sahin, Fatih Kemik, Harun Muglu, et al.
Cancers|June 26, 2026
Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group StudyBahadır Köylü, Özde Melisa Celayir, Harun Muğlu, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
The New England Journal of Medicine|June 2, 2025
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based ChemotherapyGiannis Mountzios, Longhua Sun, Byoung Chul Cho, et al.
Annals of Surgical Oncology|February 3, 2021
The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry StudyAtilla Soran, Lutfi Dogan, Arda Isik, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 10, 2026
Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group StudyNazım C Demircan, Melek Özdemir, Sevinç Ballı, et al.
Current Oncology (Toronto, Ont.)|October 28, 2025
Locoregional Treatment in De Novo Bone-Only Metastatic Breast Cancer: Prospective, Multi-Institutional Real-World Data, BOMETIN, Protocol MF14-1aAtilla Soran, Berk Göktepe, Berkay Demirors, et al.
Medicine|November 14, 2023
The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from TurkeyArif Akyildiz, Deniz Can Guven, Ahmet Anil Ozluk, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|September 12, 2015
Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinomaNedim Turan, Mustafa Benekli, Olcun Umit Unal, et al.
Medicine|May 24, 2024
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacySaadettin Kilickap, Akin Ozturk, Nuri Karadurmus, et al.
Lung Cancer (Amsterdam, Netherlands)|August 18, 2020
GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patientsNir Peled, Roni Gillis, Saadettin Kilickap, et al.
Therapeutic Advances in Medical Oncology|March 16, 2026
Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter studyTaha Koray Sahin, Fatih Kemik, Harun Muglu, et al.
Cancers|June 26, 2026
Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group StudyBahadır Köylü, Özde Melisa Celayir, Harun Muğlu, et al.
Pageof 12